Addressing antimicrobial resistance by improving access and quality of care-A review of the literature from East Africa.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
entrez:
22
7
2021
pubmed:
23
7
2021
medline:
12
11
2021
Statut:
epublish
Résumé
Universal access to healthcare, including quality medicines, is a fundamental human right but is still out of reach for many in low- and middle-income countries (LMICs). An existing framework capturing variability of access to healthcare in low-resource settings includes the 5 dimensions: availability, accessibility, affordability, adequacy, and acceptability. This framework encompasses key components, including health infrastructure and means to access it as well as service organisation, costs, and factors that influence users' satisfaction. However, in reality, the effectiveness of accessed healthcare is measured by the likelihood of a positive outcome. We therefore propose an expansion of this framework to include an additional dimension, "aspects of quality," incorporating quality, which critically influences the ability of the accessed services to generate optimal health outcomes. Within this framework, we explore literature from East Africa likely relevant to a range of LMIC contexts, mainly focusing on the provision of widely used antimicrobials such as antimalarials and antibiotics. We argue that major inadequacies exist across all 6 dimensions of access and quality of drugs and their provision. While the global focus is on curbing excessive antimicrobial use to tackle the antimicrobial resistance (AMR) crisis, major constraints around access shape patients' health-seeking decisions leading to potentially problematic practices that might exacerbate the AMR problem. We advocate for a holistic approach to tackling these inadequacies, encompassing all dimensions of access and quality of healthcare in order to improve health outcomes while simultaneously counteracting the AMR crisis.
Identifiants
pubmed: 34292932
doi: 10.1371/journal.pntd.0009529
pii: PNTD-D-21-00410
pmc: PMC8297743
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0009529Subventions
Organisme : Medical Research Council
ID : MR/S004815/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/D/20002173
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/P007767/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/D/20002174
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Malar J. 2011 Oct 26;10:316
pubmed: 22029829
Lancet Glob Health. 2014 Jun;2(6):e323-33
pubmed: 25103301
Rev Sci Tech. 2012 Apr;31(1):145-88
pubmed: 22849274
Am J Trop Med Hyg. 2009 May;80(5):737-8
pubmed: 19407116
Soc Sci Med. 2010 Nov;71(9):1593-600
pubmed: 20855143
PLoS One. 2016 Nov 15;11(11):e0165785
pubmed: 27846216
N Engl J Med. 2014 Mar 6;370(10):950-7
pubmed: 24597868
Epidemiol Infect. 2020 Feb 27;148:e40
pubmed: 32102721
PLoS One. 2008;3(10):e3403
pubmed: 18923672
Trop Med Int Health. 2007 Jan;12(1):68-74
pubmed: 17207150
Prev Vet Med. 2021 Jan;186:105212
pubmed: 33271469
Glob Public Health. 2019 May;14(5):750-763
pubmed: 30407891
Bull World Health Organ. 2004 Jul;82(7):509-15
pubmed: 15508195
Pan Afr Med J. 2018 Nov 08;31:165
pubmed: 31086618
PLoS One. 2017 Jan 26;12(1):e0170328
pubmed: 28125722
Transbound Emerg Dis. 2021 Jul;68(4):1835-1849
pubmed: 33058533
Malar J. 2007 Jun 29;6:83
pubmed: 17603898
PLoS Med. 2010 Aug 31;7(8):
pubmed: 20824175
PLoS One. 2021 May 7;16(5):e0251301
pubmed: 33961678
BMJ Open. 2013 Aug 17;3(8):e002923
pubmed: 23955188
Trop Anim Health Prod. 2000 Dec;32(6):361-74
pubmed: 11147276
PLoS One. 2013 Nov 11;8(11):e78942
pubmed: 24244390
Malar J. 2010 Jun 15;9:164
pubmed: 20550654
Health Res Policy Syst. 2011 Jun 09;9:22
pubmed: 21658259
Drugs Real World Outcomes. 2017 Mar;4(1):53-63
pubmed: 27888478
Malar J. 2017 May 19;16(1):205
pubmed: 28526075
PLoS Med. 2007 Oct;4(10):1584-8
pubmed: 17958467
Lancet. 2016 Jan 9;387(10014):188-98
pubmed: 26603919
Med Care. 1981 Feb;19(2):127-40
pubmed: 7206846
Front Pharmacol. 2017 Nov 09;8:751
pubmed: 29163151
BMJ. 2004 Nov 20;329(7476):1212
pubmed: 15542534
BMC Public Health. 2019 Apr 11;19(1):395
pubmed: 30971228
BMJ Open. 2016 Mar 15;6(3):e010632
pubmed: 26980439
Malar J. 2011 Apr 20;10:99
pubmed: 21507227
Malar J. 2017 Jan 3;16(1):6
pubmed: 28049481
Lancet. 2011 Jan 15;377(9761):228-41
pubmed: 21146207
BMC Health Serv Res. 2017 Jun 19;17(1):416
pubmed: 28629475
Trop Anim Health Prod. 2016 Dec;48(8):1633-1643
pubmed: 27580621
Lancet. 2008 Nov 8;372(9650):1661-9
pubmed: 18994664
PLoS One. 2019 Nov 19;14(11):e0225194
pubmed: 31743375
PLoS One. 2015 Jul 02;10(7):e0130305
pubmed: 26135143
East Afr Med J. 2004 Feb;Suppl:S12-6
pubmed: 15125111
Prog Community Health Partnersh. 2009 Summer;3(2):145-53
pubmed: 20208262
Health Policy Plan. 2008 May;23(3):170-8
pubmed: 18321889
PLoS One. 2020 Jan 24;15(1):e0220274
pubmed: 31978098
JAMA Netw Open. 2018 Aug 3;1(4):e181662
pubmed: 30646106
Antimicrob Resist Infect Control. 2015 Jul 21;4:30
pubmed: 26199723
Malar J. 2011 Oct 31;10:327
pubmed: 22039892
Int J Epidemiol. 2004 Oct;33(5):1080-91
pubmed: 15256523
Malar J. 2009 Jun 12;8:131
pubmed: 19523220
PLoS One. 2015 Jul 17;10(7):e0132964
pubmed: 26186547
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Malar J. 2011 Dec 20;10:377
pubmed: 22183039
PLoS One. 2019 Jan 10;14(1):e0209006
pubmed: 30629586
PLoS One. 2017 Oct 2;12(10):e0185827
pubmed: 28968447
Trop Med Int Health. 2008 Apr;13(4):487-94
pubmed: 18298605